Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14607857 | 0.94 | KDM4E (0.43) | KDM4ELMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL4583844 | 0.91 | L3MBTL1 (0.38) | KDM4ELMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL5545282 | 0.89 | KDM4E (0.55) | KDM4ELMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL5541088 | 0.88 | KDM4E (0.47) | KDM4ELMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL5547343 | 0.88 | KDM4E (0.47) | KDM4ELMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL4583709 | 0.88 | L3MBTL1 (0.39) | KDM4ELMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL4585046 | 0.87 | L3MBTL1 (0.39) | KDM4ELMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL5541141 | 0.87 | GAA (0.45) | KDM4ELMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL5538484 | 0.86 | KDM4E (0.45) | KDM4ELMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL5545287 | 0.85 | KDM4E (0.52) | KDM4ELMNAALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194523-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080194523-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080194523-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| EP-1910355-A2 | HIV INTEGRASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007019100-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194523-A1 | Hiv Integrase Inhibitors | ING2, API5, SAMHD1 | KDM4E 1183/4885LMNA 4141/4885ALDH1A1 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.